Literature DB >> 11726231

Identification of a CD8alpha(+) dendritic cell subpopulation in rat spleen and evaluation of its OX-62 expression.

M de la Mata1, C M Riera, P Iribarren.   

Abstract

Rat spleen DC and bone marrow-derived DC were isolated and characterized by morphology and flow cytometry. We found a CD8alpha(+) DC subpopulation representing 19-48% (27.4 +/- 12.0) of total spleen DC. The OX-62 expression on total spleen DC was 41-59% (51.8 +/- 7.5). Myeloid bone marrow-derived DC were negative for CD8alpha and OX-62. We demonstrated the coexpression of CD8alpha and OX-62 molecules, at least in a portion CD8alpha(+) spleen DC. Both CD8alpha(+) and CD8alpha(-) spleen DC subpopulations separated by MACS were able to induce an in vivo primary immune response to OVA. The immune response induced by the CD8alpha(-) DC subpopulation was higher (P < 0.05). We identified a CD8alpha(+) DC subpopulation in rat spleen less effective in inducing an immune response than CD8alpha(-) DC. Moreover, our results suggest the presence of DC subpopulations with different lineages in DC preparations based on OX-62 expression. (c)2001 Elsevier Science.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11726231     DOI: 10.1006/clim.2001.5124

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  2 in total

1.  After injection into the striatum, in vitro-differentiated microglia- and bone marrow-derived dendritic cells can leave the central nervous system via the blood stream.

Authors:  Sonja Hochmeister; Manuel Zeitelhofer; Jan Bauer; Eva-Maria Nicolussi; Marie-Therese Fischer; Bernhard Heinke; Edgar Selzer; Hans Lassmann; Monika Bradl
Journal:  Am J Pathol       Date:  2008-10-30       Impact factor: 4.307

2.  CD8alpha dendritic cells and immune protection from experimental allergic encephalomyelitis.

Authors:  A Pettersson; X-C Wu; C Ciumas; H Lian; V Chirsky; Y-M Huang; B Bjelke; H Link; B-G Xiao
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.